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Introduction
The Sentinel Lymph Node (SLN) is the first lymph node to receive lymphatic drainage from the site of a primary tumor, a concept established since 1977 by Cabanas, who introduced the sentinel lymph node biopsy (SLNB) in penile carcinoma 1 . In 1993, Krag et al. 2 used the technetium-99 ( 99 Tc) in SLNB for melan. In 1994, Giuliano, using the patent blue dye in breast tumor, validated the concept of sentinel lymph node (SLN) in breast cancer 3 . In 2003, Veronesi 4 established that SLNB was a safe and accurate method of screening axillary nodes for metastasis in women with small breast tumors. Recently, SLNB has replaced axillary dissection in early-stage breast cancer in clinically tumor-free patients 5 .
The association of 99 Tc with the blue dye allowed a more accurate identification in SLNB 6, 7 . Other dyes can also be used in SLN identification during the surgical procedure, such as methylene blue, patent blue, and isosulfan blue 8 however, such substances -in a recent literature review -revealed a significant number of hypersensitivity reactions 9, 10 . Patent blue dye can cause from subtle adverse effects, such as skin rash, to severe reactions of anaphylaxis 11, 12 . The use of methylene blue may be associated with serious complications such as skin and fat necrosis at the injection site 13 . Anaphylactic reactions to isosulfan blue or patent blue in patients submitted to SLNB range from 0.6% to 2.7%
.
Identifying substances with fewer side effects and/ or allergic reactions in SLNB is a challenge. In 2009, Pinheiro et al. 15 proved, in an experimental research with animals, the efficacy of hemosiderin (a protein resulting from the degradation of hemoglobin that is commonly found in lysosomes of histiocytes and Kupffer cells) as an autologous dye in SLNB of female dogs' breasts. In the present study, the association of hemosiderin with 99 Tc presented similar results in the SLNB when compared to patent blue and 99 Tc. Hemosiderin has been experimentally proven to be a potential alternative to the current dyes.
The purpose of the present research was to assess the safety and potential equivalence of the use of hemosiderin in SLNB in human breast cancer compared to the gold standard test, the 99 Tc.
Methods
This non-randomized prospective clinical study conducted with human subjects was approved by the Research Ethics Committee of the Hospital Universitário Walter Cantídio, Universidade Federal do Ceará on August 10, 2010, No. 0730710. The surgical procedures were carried out at the Maternidade Escola Assis Chateaubriand -MEAC and Hospital Universitário Walter Cantídio by one single surgeon in the period from September 2011 to November 2013.
The non-random sample comprised 14 women from the phase 1 clinical trial who were selected in the mastology outpatient clinic of the MEAC and had a confirmed histopathologic diagnosis of breast cancer, with primary tumors (T1/T2) and clinically tumor-free axilla; women were of different ages, weighted over 50 kg, and had an indication for SLNB (Table 1) .
Each patient was informed about the procedures and signed a free informed consent form prior to research participation. A week before the start of the study, all the participants underwent preoperative clinical and laboratory assessment, which showed they were able to undergo the surgical procedure. The iron metabolic profile was also assessed previously through complete blood count, serum iron, serum ferritin, transferrin saturation, and total iron-binding capacity.
Preparation, administration and production of hemosiderin
The preparation of the autologous dye derived from blood -hemosiderin -for use in the present study was obtained from a sample of 16ml of peripheral blood collected 24h before surgery. The peripheral blood drawn from the patient was inserted into two BD Vacutainer ® tubes with Buffered Sodium Citrate aseptically. Then, the blood was centrifuged at 2000 rpm for 10 minutes at 22°C. The centrifuged material separated into three phases in the test tube. The upper and intermediate layers (serum) were discarded and the bottom layer (red blood cells -RBCs) was diluted with normal saline (0.9% NaCl) in equal volume (ml) followed by manual homogenization in laminar flow biological safety cabinet. The resulting solution was centrifuged (3800 rpm for 3 minutes) again, with the appearance of two phasesthe first was discarded, and the volume withdrawn was replaced with double-distilled water in the laminar flow cabinet, causing hemolysis of RBCs. The third and final centrifugation (3800 rpm for 3 minutes) yield one single phase of lysed RBCs suspended in the reddish liquid. This hemolysate, rich in hemoglobin, which contains iron, when injected in the breast is phagocytosed by macrophages of the Reticuloendothelial System that, through the lymphatic system, saturate the sentinel lymph node of ferric hydroxyphosphate micelles, which accumulate, resulting in the formation of hemosiderin. Sterility assurance was controlled with blood cultures to detect bacteria and fungi.
Hemosiderin was injected on an outpatient basis, with the patient in supine position, asepsis of the injection site with 70% alcohol, local anesthesia with 2% lidocaine without adrenaline, in the external periareolar region of the breast (3h) via a single puncture. After that, we performed a subareolar injection of 4ml of the dye and, after removal of the needle, we pressed the puncture hole with cotton for 1 minute ( Figure 1A -B).
Patients were hospitalized and assessed as for the presentation of side effects for 24 hours. Two hours before the surgical procedure, the patient was taken to the imaging center of the clinic and underwent breast Magnetic Resonance Imaging (MRI) and received preoperative subareolar intradermal injection of 0.2ml of 99 Tc and mammary scintigraphy. After imaging tests, the patients were taken to the operating room where they, under general anesthesia, underwent the surgical procedure.
Sentinel lymph node biopsy
Patients were submitted to SLNB, with incision in the axillary fold guided by Gamma-Probe and dissection by planes until the identification of point of maximum uptake of 99 Tc, identifying the marked nodes and their colors ( Figure 1C-D) . After removal of lymph nodes, we assessed in each one the detection intensity of 99 Tc by the gamma-probe and the hemosiderin level of marking using a color scale from red to black (Figure 2 ). These data were recorded in a data collection form for further analysis. All surgical specimens were sent for pathological and immunohistochemical study. The patients were monitored throughout the procedure, since the injection of hemosiderin until the postoperative period and their return within 7, 15 and 30 days after surgery (Figure 3) . 
Results
Fourteen patients underwent SLNB with hemosiderin according to the method described. The mean age of patients was 54.3 years and the postmenopausal status was prevalent in 50% of the sample. Regarding histological type, twelve patients (85%) were diagnosed with invasive ductal carcinoma. As for the histological grade, there was a predominance of grade 2 tumors (60%) ( Table 1) .
There was no evidence of side effects, allergic reactions, surgical infection or toxicity in patients submitted to SLNB with hemosiderin in our study.
The efficacy of SLNB with hemosiderin was confirmed by determining the equivalence of hemosiderin compared to the marking technique using 
0(0%)
Pathological lymph node status pN0 10(72%)
3(23.3%)

Hormone receptor statu Estrogen receptor (ER).
(86%)
Progesterone receptor (PR).
HER2 status HER2. 0(0%) Each patient submitted to SLNB had their lymph nodes classified in percentage terms according to the shades of color found: no color-0% (n=0); light red-16% (n=2); dark-red 64% (n=8) and black-16% (n=2) ( Table 2 ). In 100% of cases (n=14), the SLN were marked and identified by gamma-probe with 99 Tc. The use of blue dyes for SLNB has increased worldwide.
Sleth et al. 16 , in their work, have reported an annual increase in the incidence of adverse reactions and increased risk of allergic reactions associated with the blue dyes; therefore, they questioned if it was not the time to change the dye. This restlessness was one of the motivations to study hemosiderin -in the present clinical study -as a dye that can substitute artificial dyes for SLNB.
Pinheiro et al. 15 have tested the feasibility of hemosiderin in laboratory as an autologous dye, compared to patent blue, for breast SLNB in a canine model. Given that original study, it was possible to base and test the use of hemosiderin for SLNB in breast cancer in women, revealing an equivalence of hemosiderin and 99 Tc with a concordance rate of 100% of the cases and an average of 2.5 SLN per patients. These findings put hemosiderin on the same level of 99 Tc, a widely used substance that is currently the "gold standard" in SLNB worldwide 7 .
As this is a phase I clinical trial with a sample of 14 women and with the aim to establish the clinical safety of the substance hemosiderin, a dye without toxicity derived from the patient, minimizes these concerns.
With the present study, hemosiderin opens a new perspective to become an important tool in SLNB. Further studies with larger samples and consistent results are needed to confirm its efficacy and safety. Therefore, it has the potential to substitute the current dyes and become the "gold standard" for SLNB.
Conclusion
Hemosiderin is an efficient and safe dye that is equivalent to 99 Tc in sentinel lymph node biopsy in breast cancer.
